Sildenafil citrate is a small molecule commercialized by Dare Bioscience, with a leading Phase II program in Female Hypoactive Sexual Desire Disorder. According to Globaldata, it is involved in 6 clinical trials, of which 4 were completed, 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Sildenafil citrate’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Sildenafil citrate is expected to reach an annual total of $81 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Sildenafil citrate Overview
Sildenafil citrate (SST-6007) is under development for the treatment of female hypoactive sexual desire disorder. The drug candidate is a small molecule applied vaginally and topically to the female genitalia. It acts by targeting phosphodiesterase 5 (PDE-5). It is developed based on KNOSIS delivery technology.
Dare Bioscience Overview
Dare Bioscience is a biopharmaceutical company that develops products for women’s reproductive health. Its product pipeline includes Ovaprene, an investigational hormone-free monthly intravaginal contraceptive designed to be worn conveniently over multiple weeks, Sildenafil creams a phosphodiesterase-5 (PDE-5) inhibitor and XACIATO for the treatment of bacterial vaginosis in females. Dare Bioscience’s other pipelines include DARE-PDMI, DARE-PDMI, DARE VVA1, DARE FRTI/PTBI, DARE-LARC1 and DARE-RH1 for the treatment of menopausal hormone therapy, primary dysmenorrhea, vulvar and vaginal atrophy, pregnancy maintenance, novel antimicrobial glycerol monolaurate, hydrogel formulation for delivery of live biotherapeutics to support vaginal health and others. The company develops and markets therapies for women in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility. Dare Bioscience is headquartered in San Diego, California, the US.
The company reported revenues of (US Dollars) US$2.8 million for the fiscal year ended December 2023 (FY2023), a decrease of 71.9% over FY2022. The operating loss of the company was US$30.9 million in FY2023, compared to an operating loss of US$31.4 million in FY2022. The net loss of the company was US$30.2 million in FY2023, compared to a net loss of US$31 million in FY2022.
For a complete picture of Sildenafil citrate’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.